Search

Now showing items 1-1 of 1

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.

Feldinger, K; Generali, D; Kramer-Marek, G; Gijsen, M; Ng, TB; Wong, JH; Strina, C; Cappelletti, M; Andreis, D; Li, J-L; Bridges, E; Turley, H; Leek, R; Roxanis, I; Capala, J; Murphy, G; Harris, AL; Kong, A (2014-08-30)

Trastuzumab prolongs survival in HER2 positive breast cancer patients. However, resistance remains a challenge. We have previously shown that ADAM17 plays a key role in maintaining HER2 phosphorylation during trastuzumab ...